AAP
GLUE icon

Arax Advisory Partners’s Monte Rosa Therapeutics GLUE Stock Holding History

Arax Advisory Partners’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$8.92K Sell
323
-137
-30% -$2.62K ﹤0.01% 2504
2025
Q4 		$7.21K Sell
460
-31,985
-99% -$431K ﹤0.01% 2655
2025
Q3 		$240K Buy
+32,445
New +$172K ﹤0.01% 1181
2025
Q2 		– Sell
-95
Closed -$441 – 3110
2025
Q1 		$441 Buy
+95
New +$583 ﹤0.01% 2546

Other funds holding GLUE

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Arax Advisory Partners's GLUE Position: Q1 2026 in Review

Arax Advisory Partners reduced its Monte Rosa Therapeutics (GLUE) stake by 30% in Q1 2026, selling an estimated $2.62K and leaving 323 shares worth $8.92K. The position accounts for ﹤0.01% of the portfolio, ranked #2504.

Arax Advisory Partners first reported a position in GLUE in Q1 2025 and has held it in 4 quarters since. The position peaked at $240K in Q3 2025. 190 funds tracked by Wall St. Rank hold GLUE as of Q1 2026.

  • Arax Advisory Partners held 323 shares of Monte Rosa Therapeutics worth $8.92K as of Q1 2026.
  • Arax Advisory Partners sold 137 Monte Rosa Therapeutics shares in Q1 2026, an estimated $2.62K.
  • Monte Rosa Therapeutics made up ﹤0.01% of Arax Advisory Partners's portfolio in Q1 2026, its #2504 holding.
  • Arax Advisory Partners first reported a position in Monte Rosa Therapeutics in Q1 2025 and has held it in 4 quarters since.
  • Arax Advisory Partners's Monte Rosa Therapeutics position peaked at $240K in Q3 2025.
  • 190 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q1 2026.

Based on Arax Advisory Partners's 13F filing for Q1 2026, filed 13 May 2026.